Anixa Biosciences Inc Financials
This page shows Anixa Biosciences Inc (ANIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development-stage spending remains dominant: R&D and overhead consume capital faster than revenue can support commercialization.
From FY2024 to FY2025, net loss narrowed from-$12.6M to-$10.9M , but operating cash flow improved only from-$7.3M to-$7.2M . That gap indicates the accounting improvement was not matched by a comparable reduction in cash requirements.
FY2024, the latest year with reported revenue, paired
The balance sheet is lightly levered: FY2025 debt-to-equity was 0.1x and current ratio was 8.1x, yet total assets fell from
Financial Health Signals
Anixa Biosciences Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Anixa Biosciences Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Anixa Biosciences Inc reported a net loss of $10.9M while operations used $7.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Anixa Biosciences Inc reported -$10.9M in net income in fiscal year 2025. This represents an increase of 13.0% from the prior year.
Anixa Biosciences Inc earned -$0.34 per diluted share (EPS) in fiscal year 2025. This represents an increase of 12.8% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Anixa Biosciences Inc held $1.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Anixa Biosciences Inc's ROE was -72.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 9.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Anixa Biosciences Inc invested $5.1M in research and development in fiscal year 2025. This represents a decrease of 20.7% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
ANIX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $210K0.0% | $210K | N/A | $512K | N/A | $250K-77.5% | $1.1M+206.9% | $363K+20.8% | $300K-96.8% | $9.3M+152.4% | $3.7M+843.1% | $389K-58.6% | $940K-6.3% | $1.0M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $4K-88.6% | $34K |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $936K-3.4% | $969K |
| R&D Expenses | N/A | $5.1M-20.7% | $6.4M+34.1% | $4.8M-28.9% | $6.7M+8.3% | $6.2M+41.3% | $4.4M-20.0% | $5.5M-19.7% | $6.8M+326.5% | $1.6M+2.6% | $1.6M+118.8% | $711K | N/A | N/A | $2.2M-29.2% | $3.1M |
| SG&A Expenses | N/A | $6.6M-10.8% | $7.4M+18.2% | $6.3M-12.3% | $7.2M+1.4% | $7.1M+26.4% | $5.6M-1.2% | $5.7M-18.1% | $6.9M+56.7% | $4.4M+62.8% | $2.7M-50.9% | $5.5M-14.0% | $6.4M-19.8% | $8.0M+179.1% | $2.9M-0.3% | $2.9M |
| Operating Income | N/A | -$11.7M+15.4% | -$13.8M-25.6% | -$11.0M+20.6% | -$13.9M-5.6% | -$13.1M-31.6% | -$10.0M+16.1% | -$11.9M+16.8% | -$14.3M-135.2% | -$6.1M-34.7% | -$4.5M-377.3% | -$945K+81.3% | -$5.0M+36.3% | -$7.9M-91.5% | -$4.1M+17.8% | -$5.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $500K-3.7% | $520K+15.1% | $452K-64.2% | $1.3M+13.9% | $1.1M+14377.0% | $8K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $600K |
| Net Income | N/A | -$10.9M+13.0% | -$12.6M-28.0% | -$9.8M+27.8% | -$13.6M-4.9% | -$13.0M-29.3% | -$10.0M+14.0% | -$11.6M+16.8% | -$14.0M-179.4% | -$5.0M+0.1% | -$5.0M-263.8% | -$1.4M+85.6% | -$9.6M+4.7% | -$10.1M-137.0% | -$4.3M+42.4% | -$7.4M |
| EPS (Diluted) | — | -$0.34+12.8% | -$0.39-21.9% | -$0.32-171.1% | $0.45 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ANIX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $16.1M-25.5% | $21.6M-15.4% | $25.5M-16.1% | $30.4M-16.1% | $36.3M+283.6% | $9.5M+50.2% | $6.3M-2.4% | $6.4M-26.8% | $8.8M+56.6% | $5.6M-39.7% | $9.3M+3.1% | $9.1M+66.5% | $5.4M-3.9% | $5.7M-34.5% | $8.6M |
| Current Assets | $15.9M-25.6% | $21.4M-15.8% | $25.4M-16.0% | $30.2M-16.1% | $36.0M+284.3% | $9.4M+53.8% | $6.1M+10.0% | $5.5M-21.0% | $7.0M+106.3% | $3.4M-50.7% | $6.9M+9.1% | $6.3M+412.4% | $1.2M+33.8% | $922K-70.5% | $3.1M |
| Cash & Equivalents | $1.2M-2.1% | $1.3M+38.9% | $915K-92.6% | $12.4M-57.6% | $29.1M+353.9% | $6.4M+83.8% | $3.5M+14.3% | $3.1M-8.5% | $3.3M+34.2% | $2.5M-43.0% | $4.4M+30.0% | $3.4M+274.2% | $898K+164.4% | $340K-56.1% | $774K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $400K+128.6% | $175K+2400.0% | $7K | N/A |
| Total Liabilities | $2.1M-21.2% | $2.7M+25.7% | $2.2M-2.8% | $2.2M+48.5% | $1.5M+25.4% | $1.2M-19.8% | $1.5M+46.1% | $1.0M+14.0% | $889K-80.8% | $4.6M+8.4% | $4.3M-15.1% | $5.0M-42.4% | $8.8M+27.8% | $6.9M-9.7% | $7.6M |
| Current Liabilities | $2.0M-21.3% | $2.5M+23.3% | $2.0M-0.4% | $2.0M+60.4% | $1.3M+6.8% | $1.2M-19.8% | $1.5M | N/A | $889K+89.8% | $469K-21.1% | $594K-67.2% | $1.8M-43.7% | $3.2M+76.2% | $1.8M-13.4% | $2.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $370K | N/A | N/A | N/A | N/A |
| Total Equity | $15.2M-24.2% | $20.0M-17.8% | $24.3M-16.2% | $29.0M-18.0% | $35.4M+304.5% | $8.8M+67.3% | $5.2M-3.7% | $5.4M-31.4% | $7.9M+702.3% | $987K-80.5% | $5.1M+26.0% | $4.0M+220.7% | -$3.3M-178.1% | -$1.2M-212.9% | $1.1M |
| Retained Earnings | -$251.7M-4.5% | -$240.8M-5.5% | -$228.2M-4.5% | -$218.4M-6.6% | -$204.8M-6.8% | -$191.8M-5.5% | -$181.8M-6.8% | -$170.2M-9.0% | -$156.2M-3.3% | -$151.2M-3.4% | -$146.1M-1.0% | -$144.8M-7.1% | -$135.2M-8.1% | -$125.1M-3.5% | -$120.8M |
Not reported in any period shown, so not listed: Inventory, Goodwill.
ANIX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.1M | -$7.2M+2.2% | -$7.3M-18.1% | -$6.2M+4.4% | -$6.5M-31.5% | -$4.9M+20.0% | -$6.2M-30.2% | -$4.7M-11.0% | -$4.3M-12.6% | -$3.8M-12.3% | -$3.4M-348.0% | $1.4M+157.3% | -$2.4M+25.3% | -$3.2M-1.5% | -$3.1M-338.7% | -$716K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $16K-91.0% | $175K+356.9% | $38K+27.2% | $30K-79.4% | $147K+167.5% | $55K+719.5% | $7K | N/A | $2K-82.3% | $9K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$6.2M-25.9% | -$4.9M-14.0% | -$4.3M-12.7% | -$3.8M-8.5% | -$3.5M-369.6% | $1.3M+154.8% | -$2.4M | N/A | -$3.1M-333.4% | -$725K |
| Investing Cash Flow | $1.5M | $4.9M+13.8% | $4.3M+176.3% | -$5.6M+47.8% | -$10.7M-173.9% | -$3.9M-1180.9% | -$306K+41.8% | -$525K-136.0% | $1.5M+153.4% | -$2.7M-281.9% | $1.5M+3224.5% | $45K+101.8% | -$2.5M-602.0% | $499K-71.4% | $1.7M+181.7% | -$2.1M |
| Financing Cash Flow | $5.2M | $2.3M-33.2% | $3.4M+833.1% | $366K-19.0% | $452K-98.6% | $31.6M+235.6% | $9.4M+65.0% | $5.7M+125.5% | $2.5M-65.8% | $7.4M+275995.0% | -$3K+99.3% | -$401K-105.5% | $7.3M+126.4% | $3.2M+238.7% | $958K-62.2% | $2.5M |
| Share Buybacks | N/A | N/A | $6K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ANIX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 99.6%+3.0pp | 96.6% |
| Operating Margin | N/A | -6586.2% | -5243.3% | N/A | -2565.6% | N/A | -4756.0% | -1284.4% | -1676.0% | -1503.0% | -10.2% | -137.5% | -2036.2% | -439.8% | -501.2% |
| Net Margin | N/A | -5978.1% | -4671.9% | N/A | -2530.1% | N/A | -4658.8% | -1258.1% | -1381.8% | -1672.1% | -14.9% | -261.9% | -2592.3% | -452.4% | -735.5% |
| Return on Equity | -72.1%-9.3pp | -62.8%-22.5pp | -40.3%+6.5pp | -46.8%-10.3pp | -36.5%+77.8pp | -114.3%+108.1pp | -222.5%+35.1pp | -257.5%-194.3pp | -63.2%+444.8pp | -508.0%-480.7pp | -27.3%+212.3pp | -239.6% | N/A | N/A | -697.3% |
| Return on Assets | -68.0%-9.8pp | -58.1%-19.7pp | -38.4%+6.3pp | -44.7%-9.0pp | -35.7%+70.3pp | -106.0%+79.1pp | -185.1%+32.0pp | -217.0%-160.2pp | -56.8%+32.3pp | -89.1%-74.4pp | -14.8%+91.3pp | -106.1%+79.2pp | -185.3%-110.2pp | -75.1%+10.2pp | -85.3% |
| Current Ratio | 8.08-0.5x | 8.54-4.0x | 12.50-2.3x | 14.83-13.5x | 28.35+20.5x | 7.88+3.8x | 4.11 | N/A | 7.89+0.6x | 7.25-4.4x | 11.61+8.1x | 3.49+3.1x | 0.38-0.1x | 0.51-1.0x | 1.48 |
| Debt-to-Equity | 0.140.0x | 0.140.0x | 0.090.0x | 0.080.0x | 0.04-0.1x | 0.14-0.1x | 0.28+0.1x | 0.19+0.1x | 0.11-4.6x | 4.70+4.6x | 0.07-1.2x | 1.26 | N/A | N/A | 7.17 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -1966.8% | -387.6% | -1055.7% | -1176.1% | 14.1%+79.2pp | -65.1% | N/A | -334.3% | -72.3% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Anixa Biosciences Inc Ranks
Frequently Asked Questions
Is Anixa Biosciences Inc profitable?
No, Anixa Biosciences Inc (ANIX) reported a net income of -$10.9M in fiscal year 2025.
What is Anixa Biosciences Inc's return on equity (ROE)?
Anixa Biosciences Inc (ANIX) has a return on equity of -72.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Anixa Biosciences Inc's operating cash flow?
Anixa Biosciences Inc (ANIX) recorded an outflow of $7.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Anixa Biosciences Inc's total assets?
Anixa Biosciences Inc (ANIX) had $16.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Anixa Biosciences Inc spend on research and development?
Anixa Biosciences Inc (ANIX) invested $5.1M in research and development during fiscal year 2025.
What is Anixa Biosciences Inc's current ratio?
Anixa Biosciences Inc (ANIX) had a current ratio of 8.08 as of fiscal year 2025, which is generally considered healthy.
What is Anixa Biosciences Inc's debt-to-equity ratio?
Anixa Biosciences Inc (ANIX) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Anixa Biosciences Inc's return on assets (ROA)?
Anixa Biosciences Inc (ANIX) had a return on assets of -68.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Anixa Biosciences Inc's Piotroski F-Score?
Anixa Biosciences Inc (ANIX) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Anixa Biosciences Inc's earnings high quality?
Anixa Biosciences Inc (ANIX) reported a net loss of $10.9M while operations used $7.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.